Renal Vascular Response to Angiotensin II Administration in Two Kidneys-One Clip Hypertensive Rats Treated with High Dose of Estradiol: The Role of Mas Receptor.
Journal
International journal of vascular medicine
ISSN: 2090-2824
Titre abrégé: Int J Vasc Med
Pays: United States
ID NLM: 101542608
Informations de publication
Date de publication:
2021
2021
Historique:
received:
02
11
2020
revised:
15
01
2021
accepted:
23
01
2021
entrez:
22
3
2021
pubmed:
23
3
2021
medline:
23
3
2021
Statut:
epublish
Résumé
High blood pressure is one of the most important causes of death around the world. The renin-angiotensin system (RAS) and estradiol are two important items that regulate arterial blood pressure in women. However, hypertension, RAS, and sex hormone estradiol may influence renal vascular responses. This study was designed to determine the role of Mas receptor (MasR) on renal vascular response to angiotensin II (Ang II) administration in two kidneys-one clip (2K1C) hypertensive rats treated with estradiol. The ovariectomized rats were subjected to 2K1C or non-2K1C and simultaneously treated with estradiol (500 A779 or its vehicle did not alter mean arterial pressure (MAP), renal perfusion pressure (RPP), and renal blood flow (RBF). However, in non-2K1C rats, Ang II infusion decreased RBF and increased renal vascular resistance (RVR) responses in a dose-related manner ( Hypertension induced by 2K1C may attenuate the role of A779 and estradiol in renal vascular responses to Ang II infusion. Perhaps, this response can be explained by the reduction of Ang II type 1 receptor (AT1R) expression in the 2K1C hypertensive rats.
Sections du résumé
BACKGROUNDS
BACKGROUND
High blood pressure is one of the most important causes of death around the world. The renin-angiotensin system (RAS) and estradiol are two important items that regulate arterial blood pressure in women. However, hypertension, RAS, and sex hormone estradiol may influence renal vascular responses. This study was designed to determine the role of Mas receptor (MasR) on renal vascular response to angiotensin II (Ang II) administration in two kidneys-one clip (2K1C) hypertensive rats treated with estradiol.
METHOD
METHODS
The ovariectomized rats were subjected to 2K1C or non-2K1C and simultaneously treated with estradiol (500
RESULTS
RESULTS
A779 or its vehicle did not alter mean arterial pressure (MAP), renal perfusion pressure (RPP), and renal blood flow (RBF). However, in non-2K1C rats, Ang II infusion decreased RBF and increased renal vascular resistance (RVR) responses in a dose-related manner (
CONCLUSION
CONCLUSIONS
Hypertension induced by 2K1C may attenuate the role of A779 and estradiol in renal vascular responses to Ang II infusion. Perhaps, this response can be explained by the reduction of Ang II type 1 receptor (AT1R) expression in the 2K1C hypertensive rats.
Identifiants
pubmed: 33747565
doi: 10.1155/2021/6643485
pmc: PMC7943267
doi:
Types de publication
Journal Article
Langues
eng
Pagination
6643485Informations de copyright
Copyright © 2021 Samira Choopani and Mehdi Nematbakhsh.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Regul Pept. 2005 Jan 15;124(1-3):7-17
pubmed: 15544836
Acta Physiol (Oxf). 2012 Oct;206(2):150-6
pubmed: 22775972
Hypertension. 2005 Oct;46(4):937-42
pubmed: 16157793
Hypertension. 2010 Oct;56(4):658-66
pubmed: 20713916
Regul Pept. 2013 Jun 10;184:54-61
pubmed: 23523569
Kidney Int. 2005 Apr;67(4):1453-61
pubmed: 15780097
Am J Physiol Regul Integr Comp Physiol. 2008 Apr;294(4):R1220-6
pubmed: 18287217
Am J Physiol Renal Physiol. 2019 Sep 1;317(3):F670-F682
pubmed: 31339773
J Renin Angiotensin Aldosterone Syst. 2011 Dec;12(4):413-9
pubmed: 21436210
Regul Pept. 2012 Aug 20;177(1-3):12-20
pubmed: 22561449
Am J Physiol. 1993 Dec;265(6 Pt 2):F853-62
pubmed: 8285218
Am J Physiol Renal Physiol. 2016 Jul 1;311(1):F195-206
pubmed: 26823279
J Am Soc Hypertens. 2016 Oct;10(10):753-754
pubmed: 27660007
Physiol Rev. 2018 Jan 1;98(1):505-553
pubmed: 29351514
Am J Physiol Regul Integr Comp Physiol. 2012 Jan 1;302(1):R159-65
pubmed: 22031787
J Hypertens. 2009 Oct;27(10):1988-2000
pubmed: 19593210
Hypertension. 2001 May;37(5):1199-208
pubmed: 11358929
Pharmacol Rev. 2007 Sep;59(3):251-87
pubmed: 17878513
Circulation. 2016 Jan 26;133(4):e38-360
pubmed: 26673558
Gend Med. 2012 Feb;9(1):21-32
pubmed: 22266307
Clin Nephrol. 1993 Jun;39(6):312-20
pubmed: 8334758
Cardiology. 1990;77 Suppl 2:25-30
pubmed: 2198093
Am J Physiol Heart Circ Physiol. 2005 May;288(5):H2177-84
pubmed: 15626687
J Mol Med (Berl). 2001 Apr;79(2-3):76-102
pubmed: 11357942
Front Endocrinol (Lausanne). 2014 Jan 09;4:201
pubmed: 24409169
Adv Pharmacol Sci. 2015;2015:682745
pubmed: 26681937
Biol Sex Differ. 2010 Nov 05;1(1):6
pubmed: 21208466
Cardiovasc Res. 2004 Jun 1;62(3):587-93
pubmed: 15158151
Hypertension. 2008 Oct;52(4):666-71
pubmed: 18711010
Am J Physiol. 1999 Jul;277(1):F75-83
pubmed: 10409300
Hypertension. 1999 Jan;33(1):96-101
pubmed: 9931088
Am J Physiol Renal Physiol. 2011 Mar;300(3):F749-55
pubmed: 21209009